|
|
|
|
Selective Killing of Leukemia and Lymphoma Cells Ectopically Expressing hCGb by a Conjugate of Curcumin with a
Selective Killing of Leukemia and Lymphoma Cells Ectopically Expressing hCG by a Conjugate of Curcumin with an Antibody against hCG Subunit Hemant K.Vyasa, Rahul Palb, Ram Vishwakarmac, Nirmal K. Lohiyad, G.P. Talwara aTalwar...
|
|
|
Acute Myeloid Leukemia - Scientists at INSERM describe research in acute myeloid leukemia
According to a study from Toulouse, France, 'Most chromosomal translocations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) involve oncogenes that are either up-regulated or form part of new chimeric genes.
|
|
|
[Leukemia and Bone Marrow Transplantation] Phosphoinositide-Phospholipase C {beta}1 Mono-Allelic Deletion Is A
Phosphoinositide-Phospholipase C 1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia Matilde Y.Follo, Carlo Finelli, Cristina Clissa, Sara Mongiorgi, Costanza Bosi,...
|
|
|
LETTER: Help family whose child is battling cancer
In our midst is a family, a loving and generous family, experiencing one of the most difficult events of life: a child with cancer.Emily Kapke is a brilliant and beautiful third grader. The daughter of Bill and Deb, and little sister of...
|
|
|
Azacitidine Approved in EU for Myelodysplastic Syndromes, AML
-- The European Commission has approved azacitidine (Vidaza) for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according...
|
|
|
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
- (NewsRx.com) -- Biopure Corporation (NASDAQ:BPUR) announced that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen...
|
|
|
TopAbstracts in Leukemias 12/24/2008
TopAbstracts in Leukemias are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 7 days.Over 2000 peer-reviewed...
|
|
|
Azacitidine Approved in EU for Myelodysplastic Syndromes, AML
Recent news - Myelodysplastic Syndrome Decitabine Improves Progression-Free Survival Compared With Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome: Presented at ASH- (DGDispatch) FDA Approves...
|
|
|
LETTER: Help family whose child is battling cancer
In our midst is a family, a loving and generous family, experiencing one of the most difficult events of life: a child with cancer.Emily Kapke is a brilliant and beautiful third grader. The daughter of Bill and Deb, and little sister of...
|
|
|
LETTER: Help family whose child is battling cancer
In our midst is a family, a loving and generous family, experiencing one of the most difficult events of life: a child with cancer.Emily Kapke is a brilliant and beautiful third grader. The daughter of Bill and Deb, and little sister of...
|
|
|
Celgene Gets European Commission Marketing Approval For Cancer Drug Vidaza - Update
Tuesday, Celgene Corp.(CELG: News ), said its cancer drug candidate, Vidaza, has been granted full marketing authorization by the European commission for treating adult patients with Intermediate-2 and Higher-Risk Myelodysplastic...
|
|
|
European Commission Grants Vidaza Full Marketing Authorization for the Treatment of Patients with Higher-Risk
- Celgene International Srl (Nasdaq:CELG): First and Only Epigenetic Cancer Therapy Proven to Significantly Extend Survival for Patients with Intermediate-2 and Higher-Risk MDS and AML First Approved Therapy Effective across Broad Range of...
|
|
|
EpiCept Announces Health Canada's Approval For Ceplene Filing For The Treatment Of Acute Myeloid Leukemia
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) has announced that, at a recent pre-New Drug Submission (pre-NDS) meeting with representatives of Health Canada, it received permission to proceed with a New Drug Submission (NDS)...
|
|
|
Medical News: EpiCept Announces Health Canada's Approval For Ceplene Filing For The Treatment Of Acute Myeloid
Lymphoma / Leukemia News Main Category: Lymphoma / Leukemia Also Included In: Regulatory Affairs / Drug Approvals email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public:...
|
|
|
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leuke
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2008 DEC 25 - (NewsRx.com) -- Sunesis...
|
|
|
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
- /PRNewswire-FirstCall/ -- Biopure Corporation announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen...
|
|
|
Drug helps acute myeloid leukemia patients
A French-led international study suggests acute myeloid leukemia patients treated with Vidaza (azacitidine) have significantly increased overall survival.Acute myeloid leukemia is a cancer in which abnormal...
|
|
|
Biopure Submits IND Application For Proposed Clinical Trial In Patients With Acute Myeloid Leukemia
Biopure Corporation (Nasdaq: BPUR) announced that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen therapeutic Hemopure...
|
|
|
Drug helps acute myeloid leukemia patients
A French-led international study suggests acute myeloid leukemia patients treated with Vidaza (azacitidine) have significantly increased overall survival.Acute myeloid leukemia is a cancer in which abnormal...
|
|
|
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
- /PRNewswire-FirstCall/ -- Biopure Corporation announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen...
|
|
|
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
CAMBRIDGE, Mass., Dec.17 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2...
|
|
|
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
CAMBRIDGE, Mass., Dec.17 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2...
|
|
|
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
CAMBRIDGE, Mass., Dec.17 /PRwire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2...
|
|
|
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
CAMBRIDGE, Mass., Dec.17 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2...
|
|
|
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
Biopure Corporation (Nasdaq: BPUR) announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen therapeutic...
|
